Analyzing Healthcare M&A Trends: Q1 2024 Insights Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment. LEARN MORE
News Leerink Partners Announces Strategic Hires, Advancing Buildout of World Class Mergers & Acquisitions Team November 2024
News Tom Davidson Joins Leerink Partners as Co-President and Co-Head of Global Investment Banking November 2024
News Leerink Partners Expands Healthcare Medical Technology, Life Science Tools and Diagnostics Team with the Addition of Industry Veterans Dr. Bernhard Sakmann and Justin Reed October 2024
News Leerink Partners’ Affiliate, MEDACorp, Launches the Center for Pharmacoeconomics to Evaluate the Societal Impact of Healthcare Treatments October 2024
